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Summary. The syntheses of dichlorobis(cycloalkylamine)platinum(II) complexes with cis and trans 
cycloalkytamine ligands [cis-PtC12(C3HsNH2)  to cis-PtC12(CaHlsNH2)2 (3-8) and trans-PtC12- 
(CTH13NH2)2 (9) and trans-PtC12(CsH~sNH2)2 (10)] are described. The distinction between cis and 
trans isomers was achieved by ~H-NMR spectroscopy. The antitumor activity was determined on the 
cell proliferation of the human MDA-MB-231 breast cancer ceil line during long-term drug exposure. 
The complexes with small cycloalkylamine ligands (3-6) were inferior, those with large cycloalkylamine 
ligands were comparable (7) or superior (8) to cisplatin. Surprisingly, the cis/trans isomers 7/9 and 
8/10 were equally active. All cycloalkylamine ligands were inactive. IR-spectroscopic studies howed 
that the size of the cycloalkylamine ring does not lead to significant differences in the Pt-C1 binding 
strength. Therefore it is assumed that the markedly stronger antitumor activity of the higher 
homologues, 7-10, is not the result of a faster eaction with bionucleophils such as DNA. A possible 
explanation of the high activity of 7-10 is the strong lipophilicity of the complexes. This assumption 
was confirmed by toxicity tests against confluent cultures. 
Keywords. cis- and trans-Dichlorobis(cycloalkylamine)platinum(II) complexes; Antitumor activity; 
MDA-MB-231 Breast cancer cell line. 
Dichlorobis(eycloalkylamin)platin(II)-Komplexe. Struktur- Wirkungsbeziehungen an der mensehliehen 
MDA-MB-231 Brustkrebszellinie 
Zusammenfassung. Die Synthese von Dichlorobis(cycloalkylamin)platin(II)-Komplexen mit cis- und 
trans-st~ndigen Cycloalkylaminliganden [cis-PtC12(C3HsNH2)  bis cis-PtCI2(CsH15NH2)2 (3-8) 
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sowie trans-PtC12(CTH13NH2) 2 (9) und trans-PtClz(CaHlsNH2) 2 (10)] wird beschrieben. Eine 
Unterscheidung zwischen cis- und trans-Isomeren konnte mit Hilfe der iH-NMR-Spektroskopie 
getroffen werden. Die tumorwachstumshemmende Wirkung wurde im Langzeitversuch an der 
menschlichen MDA-MB-231 Brustkrebszellinie b stimmt. Die Komplexe mit kleinen Cycloalkyl- 
aminliganden (3-6) waren weniger, diejenigen mit groBen Cycloalkylaminliganden v rgleichbar (7) 
oder besser (8) wirksam als Cisplatin. Uberraschenderweise waren die cis/trans Isomeren 7/9 und 8/10 
gleich aktiv. S~imtliche Cycloalkylaminliganden waren unwirksam. IR-spektroskopische Unter- 
suchungen zeigen, dab die Gr6Be des Cycloalkylaminliganden zu keiner signifikanten Ver~inderung 
der Pt-C1 Bindungsst/irke ffihrt. Es wird angenommen, dab die deutlich st/irkere Antitumoraktivit/it 
der h6heren Homologen 7-10 nicht auf eine schnellere Reaktion mit Bionucleophilen wie der DNA 
zurtickzufiihren ist. Eine m6gliche Erklfirung der hohen Aktivit~it yon 7-10 liegt in der starken 
Lipophilie der Komplexe. Diese Annahme wird durch Cytotoxizit/itstests an station~iren Kulturen 
gestfitzt. 
Introduction 
The synthesis of the homologous cis-dichlorobis(cycloalkylamine)platinum(II) 
complexes 3-8* and of the trans-isomers of 3-6 as well as their antitumor activity 
(against he ADJ/PC6 plasmacytoma of the mouse) have been described I-1-3]. A 
simple correlation between activity and molecular size, which is known for 
homologous series of numerous drugs (e.g. antimicrobial agents), was not detectable. 
The first three homologues of the cis-series (3-5) proved to be equipotent. For 
a 90~ inhibition of tumor growth, comparable doses were required (ID90 
2.5 mg/kg; cisplatin: ID9o = 1.6 mg/kg). To achieve the same effect with the higher 
homologues, approximately a 5-, 3-, or 100-fold dosage of compounds 6, 7, and 8, 
had to be applied. In accordance with these findings no continuous elevation of 
activity with increasing lipophilicity of the homologues was observed I-2]. However, 
toxicity markedly decreased with growing ring size. 
In contrast o the cis-configurated complexes 3-6, their trans isomers showed 
no or only marginal effects on the ADJ/PC6 tumor, which was ascribed to small 
amounts of the related cis-isomers contained in the probes I-2]. In the study of 
Braddock et al. 1,2] compound 5, which in contrast to compound 6 was active 
against various tumor models (L1210 leukemia, Walker 256 carcinosarcoma), 
proved to be the most interesting representative. Due to its remarkable antitumor 
activity (ADJ/PC6: ID90=2.4mg/kg ) and its low toxicity (ADJ/PC6: LD50= 
480 mg/kg), the therapeutic index** of this complex is more favorable than that of 
cisplatin (5: TI = 200; cisplatin: TI = 8.1). 
These interesting results prompted us to reevaluate the antitumor activity of the 
homologous cis-dichlorobis(cycloalkylamine)platinum(II) complexes (3-8). In this 
study the trans isomers of 7 and 8, whose tumor inhibiting properties were unknown, 
were included. The antitumor effect was determined on the human MDA-MB-231 
breast cancer cell line by means of an in vitro chemosensitivity microassay described 
by Bernhardt et al. I-4]. By this method the change of the growth curves of tumor 
cell lines under the influence of test compounds i registered. A kinetic assay yields 
more exact data on the antitumor activity than the conventional single-end-point 
* The numbers of the compounds correspond to the size of the cycloalkylamine rings; compare Table 1. 
** TI is defined as the ratio LDso/ID90. 
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determination. I  addition, it provides information on the mode of drug action, 
cytostatic or cytocidal, and on a possible development of secondary resistance [4]. 
The crystal violet staining technique used provides a measure for the reproductive 
potential of the culture. The results obtained in this test series are used to disCuss 
the structure activity relationship of the complexes. 
In the pharmacological experiments described by Connors et al. [1-3] an exact 
analysis of the used complexes by spectroscopic methods allowing the unequivocal 
assignment to the cis- or trans-series i missing. So we have also reconsidered the 
configuration and the isomeric purity of the cis-dichlorobis(cycloalkylamine)- 
platinum(II) complexes 3-8 using 1H-NMR-, IR-, Raman- and UV-vis-spectro- 
scopy, as well as X-ray diffractometry [5, 6]. 
Experimental Part 
Reagents were used in the highest commercially available purity: Cyclopropylamine (Merck, > 98~), 
cyclobutylamine (Aldrich, 98~), cyclopentylamine (Merck, 99~), cyclohexylamine (Aldrich, > 99~), 
cycloheptylamine (Aldrich, 99~), cyclooctylamine (EGA, 99~), K2PtCI~ (Degussa, 46.75~ Pt), 
potassium iodide (Merck, p.a.), potassium chloride (Merck, p.a.), silver nitrate (Merck, p.a.), 
dimethylformamide (Merck, > 99.8~). 
Synthesis Procedures 
Method A [7] (Scheme 1): 
K2PtC14 (0.422 g, 1.02 x 10- 3 mol) and KI (0.678 g, 4.08 x 10- 3 mol) were dissolved in bidistilled water 
(10 ml) and stirred at room temperature for ~ 3 h. Then cyclopropylamine (0.116 g, 2.03 x 10-3 mol) 
was added. After 1 h the yellow cis-bis(cyclopropylamine)diiodoplatinum(II) precipitated and was 
filtered off. To change the leaving groups, the diiodoplatinum(II) complex was stirred in 21 ml of a 0.1 
M aqueous ilver nitrate solution (pH ~ 2.5) for 12 h. Precipitated AgI was removed by filtration, and 
KC1 (0.152 g, 2.04 x 10- a mol) was added to the filtered solution. The mixture was kept in a refrigerator 
at 6 °C for two days. The pale yellow product 3 was filtered off, washed with small amounts of water, 
methanol, and diethyl ether, and dried under vacuum. Yields are summarized in Table 2. 
Method B [1]: 
K2PtC14(0.3478 g, 8.38 x 10 .4 mol) was dissolved in bidistilled water (10 ml). Then cyclobutylamine 
(0.104 g, 1.46 x 10- 3 mol) was added (pH ~ 8.2). The mixture was stirred at room temperature for ~ 2 h. 
The pale yellow product 4 was filtered off, washed with water, methanol and diethyl ether, and dried 
under vacuum. Yields are summarized in Table 2. 
Method C: 
Preparation of the trans compounds was based on the tendency of the complexes to interconvert in
solution. The mixture of cis and trans compounds obtained by the preparation of dichlorobis(cyclo- 
heptylamine)platinum(II) according to method B (K2PtC14:0.403 g, 9.71 x 10-4 tool; cycloheptylamine: 
0.192 g, 1.7 x 10-a mol) was dissolved in DMF. The solvent was allowed to evaporate spontaneously 
within two months. The residing solid product was washed with water, methanol, and diethyl ether, 
and dried under vacuum. Yields are summarized in Table 2. 
Spectroscopic Methods 
1H-NMR spectra were recorded on a PFT-NMR spectrometer (Bruker, model WM250) at 250 MHz. 
Dimethylformamide-d 7 was used as solvent. The powder diffraction spectra were recorded with a 
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focusing monochromatic transmission diffractometer (STOE, model STADI P). IR spectra were 
recorded with a FTIR spectrometer (NICOLET, model 60 SX); resolution was set to 4 cm- 1. 
MDA-MB-231 Human Breast Cancer Cell Line and Culture Conditions 
The MDA-MB-231 human breast cancer cell line [8] (ATCC no. HTB 26) was obtained from the 
American Type Culture Collection (ATCC, Rockville, MD, USA). Cells were grown in a humified 
atmosphere of 5~ CO2 at 37 °C in McCoy 5a medium (Sigma), containing NaHCO3 (2.2 g/l), 
gentamicin (40 gg/ml, Gibco) and 10~ newborn calf serum (Gibco). The cells were harvested with 
trypsin (0.05~o)/EDTA (0.02~) (Boehringer). 
Drugs 
Cisplatin (gold label) was purchased from Aldrich, carboplatin, 2,4-dinitrophenol (DNP) and rotenone 
from Sigma. 
For chemosensitivity testing the cycloalkylamine ligands, the compounds 3-10 and cisplatin were 
dissolved in spectrophotometric grade DMF (Aldrich). DNP and rotenone were dissolved in p.a. 
EtOH (Merck), whereas carboplatin solutions were prepared with millipore filtered water. 
Chemosensitivity Assays 
Determination ofDrug Effects on Proliferating Cultures 
Two test series were carried out. The platinum complexes were assayed in passage 87, the 
cycloalkylamine ligands in passage 146. The cells were plated (100 gl/well) in 96-well microplates at a 
density of about 19 cells/microscopic f eld (Leitz Diavert, 320 x ) and were allowed to attach. After 3 
days, the medium was removed by suction and replaced with fresh medium (200 gl/well) containing 
drug (drugs were added as a 1000-fold stock solution in DMF) or pure solvent. On every plate the 
rows 5 and 6 (n = 16) served as controls, whereas two vertical rows (n = 16) per drug concentration 
were used. After varying times of incubation the cells were fixed with glutaraldehyde and stored under 
PBS at 4 °C. The PBS contained NaC1 (8 g), KC1 (0.2 g), Na2HPO4.2H20 (1 g), NaH2PO4.H20 
(0.15 g) and KH2PO4 (0.2 g) in 11 H20. All plates were stained with crystal violet simultaneously. The 
processing procedure and data analysis were performed as described by Reile et al. [9]. Drug effects 
were calculated as corrected T/C values, defined according to: 
(T/C)corr(%) = {(T - Co)/(C - Co)} x 100 (1) 
where T is the absorbance (578 nm) of the treated cells, C the absorbance of the controls and Co the 
absorbance at the time (t = 0) when drug was added. 
Experimental errors of (T/C) .... were calculated as described in [4] and are represented by 
error-bars in the figures. 
Determination ofDrug Effects on Stationary Cultures 
To quantitate "basal" toxicity the cells (in passage 146) were seeded in microplates (200 gl/well) at 
a density of about 50 cells/field of vision (320 x ). After 6 days, when the cultures had reached confluence 
(absorbance at 578 nm was about 2), the culture medium was replaced with 200 gl of fresh medium 
containing drug or pure solvent, as described above. At the time points indicated in Fig. 7 the cells 
were fixed, stained and processed simultaneously at the end of the experiment. 
The extent of drug induced cell kill, i.e. disintegration ofthe cells (cf. [4]), was calculated according 
to: 
cell kill (~) = {(C O - T)/Co} x 100 (2) 
where Co is the mean absorbance ofthe culture when drug was added and T the mean absorbance of 
the treated cells at varying times of drug exposure. 
Dichlorobis(cycloalkylamine)platinum(II) Co plexes 591 
Results 
Preparation and Characterization ofthe Complexes 
In square-planar complexes the coordination of one ligand to the metal ion 
influences the bonding between the metal ion and every other ligand [10-12]. This 
trans directing effect, a kinetic phenomenon, has extensively been used to prepare 
the isomeric forms of diamminedichloroplatinum(II). The cis isomer (cisplatin) is the 
product of the reaction of K2PtC14 with aqueous ammonia buffered with NH4C1 
[13], while trans-diamminedichloroplatinum(II) (transplatin) results from the 
reaction of [Pt(NH3),]C12 with hydrochloric acid [13]. 
One has to be aware that besides the trans directing effect of the coordinating 
ligands, the size of the ligands determines the place of substitution. The thermo- 
dynamically stable form of the PtC12am 2 (am = cycloalkylamine) complexes i the 
trans isomer [103. Therefore, in aqueous KC1 solution cisplatin undergoes a
conversion from the cis to the trans isomer with a half-life of 1.8 years at 37 °C [14]. 
The isomerization is more rapid when cycloalkylamines are used as ligands. 
Complex 4 shows a conversion to the trans isomer during the process of 
recrystallization [15]. Zanotti et al. [16] and Bradford et al. [17] tried to prepare 
crystals of 6 and 7, respectively. In each case the corresponding trans isomer was 
obtained. Therefore, for preparation of the PtC12am 2 complexes (3-10) (see Table 
1), various synthetic routes must be employed (method A-C; Scheme 1). 
We have used method A to prepare compounds 3, 7, and 8, and method B for 
compounds 4-6. The purity of the products (see Table 2) was verified by elemental 
analyses. 
The coordination of the cycloalkylamines to platinum was confirmed by 
~H-NMR spectroscopy. Due to the deshielding effect of the metal atom the 
coordination of the cycloalkylamines to platinum results in a low field shift of the 
NH signals. These signals can be used to assign the platinum complexes 3-10 either 
to the cis or the trans form. The 1H-NMR spectra of the complexes in the region 
typical for the NH resonance are shown in Fig. 1. Detailed 1H-NMR data are listed 
in Table 3. 
For compounds 7 and 8 (with am--cycloheptylamine and cyclooctylamine, 
respectively) synthesized according to method B as described by Connors et al. [1], 
two resonances in the NH region were detectable, which could result either from 
different conformeric structures or a cis/trans isomer mixture. To exclude the 
H20 
K2[PtC14]+ 4I(I ~ K2[PtI4] + 4KC1 
H20 
K2[PtI4] + 2R-NH 2 ~ PtI2(R-NH2) 2+ 2KI 
H20 
Pt I2(B.-NH2) 2 + 2 AgNO 3 ~ [Pt(H20)2(R-NH2)2 ] + + 2 NO~ + 2 AgI 
H20 
[Pt(H20)2(R-NH2)2 ] ++ 2 C1- ~ PtC12(R-NH2)  
Scheme 1.Preparation route according tomethod A [9] (R-NH2 - cycloalkylamine). The products 
PtI2(R-NH2)2, AgI, and PtC12(R-NH2)  precipitate shifting the equilibrium far to the right 
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Table 1. Dichlorobis(cycloalkylamine)platinum(II) co plexes [PtClz(C,H/,_ 1)2] 
used in this study 
Compound CnH2n- 1 Leaving Geometric 
group configuration 
3 C3HsNH 2 C1- cis 
4 C4H7NH2 C1- cis 
5 CsH9NH 2 C1- cis 
6 C6H 11NH2 C1- cis 
7 C7H13NH2 C1- cis 
8 CsHlsNH2 C1- cis 
9 CTH13NH 2 C1- trans 
10 CsH 15NH2 CI- trans 
compound 1 = cisplatin, cis-Pt(NH3)2C12 
compound 2 =- carboplatin, cis-Pt(NH3)2(cyclobutane-1,1-dicarboxylato) 
Table 2. Analytical data of dichlorobis(cycloalkylamine)platinum(II) co plexes 
Comp. Prep. Yield C (~o) H (~o) N (~o) 
method (~o) 
Calc. Found Calc. Found Calc. Found 
3 A 32 18.96 18.89 3.71 3.60 7.37 7.31 
4 B 19 23.54 23.73 4.44 4.22 6.86 6.87 
5 B 20 27.53 27.64 5.08 4.76 6.42 6.46 
6 B 21 31.04 31.27 5.64 5.41 6.03 5.96 
7 A 34 34.15 33.96 6.14 5.99 5.69 5.85 
7 B 39 34.15 33.95 6.14 6.29 5.69 6.01 
8 A 31 36.92 36.58 6.58 6.49 5.38 5.50 
8 B 18 36.92 37.36 6.58 6.65 5.38 5.48 
9 C 89 34.15 34.29 6.14 6.07 5.69 5.75 
10 C 82 36.92 36.60 6.58 6.70 5.38 5.34 
presence of two different conformers, a temperature dependent 1H-NMR study 
was performed with 7. The two NH signals for dichlorobis(cycloheptylamine)- 
platinum(II) (7) showed no change in intensity over the temperature ange between 
253 and 373 K. 
The trans-configuration ofthe side product of 7 (i.e., 9) was established by X-ray 
diffractometry. Using the atomic positions of trans-dichlorobis(cycloheptylamine)- 
platinum(II) found by Bradford [173 we have calculated the expected powder 
diffractogram ofthis compound. The more intensive reflections of 9 were also found 
in the diagram of the cis-product 7, which we obtained with method B. Thus, the 
additional NH resonances visible in the 1H-NMR spectra of 7 and 8 synthesized by 
method B (Fig. 1) were assigned to the trans isomers 9 and 10. The high field shift 
of the NH signal of the trans compound, as compared to the shift of the cis isomer, 
is in good agreement with the values for the isomers of dichlorobis(pentane- 
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compound 
3 
4 
7 
/3 
i 
5'.0 4'.5 4 .0ppm 
Fig. 1. 1H-NMR spectra of dichlorobis(cycloalkylamine)platinum- 
(II) complexes (250 MHz, DMF-dT). Compound 3 was prepared by 
method A and compounds 4 through 8by method B
1-amine)platinum(II) measured by Cherchi et al. [18]. From the integrals of the 
respective 1H-NMR signals, the ratio of the two isomeric forms of dichloro- 
bis(cycloheptylamine)platinum(II) amounts to cis:trans ~ 20:1, and for dichlorobis- 
(cyclooctylamine)platinum(II) to cis: trans ~ 2:1. The ratio of the cis/trans products 
depends on the ratio of the educts. The higher the concentration ofthe amine ligand, 
the higher the fraction of the trans isomer formed. In view of this result, we have 
used a molar ratio amine:K2PtC14 ~ 1.75:1 for the preparation of the cis isomers 
(7 and 8) (Method B). Nonetheless, products 7 and 8 contained substantial amounts 
of the trans isomers. 
Table 3. 1H-NMR data of dichlorobis(cycloalkylamine)platinum(II) co plexes (250 MHz, DMF-d7) 
Compound Prep. 6 (ppm) 
method 
NH CH (methine) CH (alkyl) 
3 A 5.05 (br, 4H) 2.61 (br, 2H) 0.61-0.83 
4 B 5.13 (br, 4H) 3.68 (br, 2H) 1.53-2.36 
5 B 4.96 (br, 4H) 3.55 (br, 2H) 1.45-2.19 
6 B 4.89 (br, 4H) 2.92 (br, 2H) 0.98-2.53 
7 A 4.87 (br,4H) 3.14 (br, 2H) 1.32-2.57 
7 B 4.88 (br, 3.8H) 3.17 (br, 2H) 1.33-2.53 
4.27 (br, 0.2H) 
8 A 4.82 (br, 4H) 3.24 (br, 2H) 1.39-2.44 
8 B 4.84 (br, 2.6H) 3.21 (br, 2H) 1.40-2.42 
4.22 (br, 1.4H) 
9 C 4.25 (br, 4H) 3.05 (br, 2H) 1.33-2.42 
10 C 4.24 (br, 4H) 3.15 (br, 2H) 1.38-2.41 
(s, 8H) 
(s, 12H) 
(s, 16H) 
(m, 20H) 
(m, 24H) 
(m, 24H) 
(m, 28H) 
(m, 28H) 
(s, 24H) 
(m, 28H) 
594 J. Kritzenberger t al. 
L 3 
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Fig. 2, 1H-NMR spectra of dichlorobis(cycloalkylamine)platinum- 
(II) complexes (250 MHz, DMF-dT). Trace (1): mixture of compounds 
7 and 9 as obtained by preparation method B; trace (2): pure trans 
compound 9 prepared by method C; trace (3): pure cis compound 7 
prepared by method A
Table4. Coupling constants 2Jpt_ H of 
dichlorobis(cycloalkylamine)platinum(II) 
complexes 
Compound 2Jpt H 
3 66 Hz 
4 64 Hz 
5 65 Hz 
6 66 Hz 
7 66 Hz 
8 66 Hz 
9 54 Hz 
10 56 Hz 
z6o ado 460 aoo 
[era  -1] Fig. 3. IRspectraofthecompounds9(upper trace) and 7 (lower trace) 
According to Lock et al. [-15-I recrystallization of the compounds 7 and 8 
in dimethylformamide yi lds compounds 9 and 10 due to a complete conversion i to 
the corresponding trans isomers (method C). 
For preparation of the pure cis isomers 7 and 8 we used the stronger trans 
directing effect of iodide compared to chloride [10-123 . Preparation using method 
A yielded the pure cis isomers of 7 and 8. The 1H-NMR spectra of 7 and 9 obtained 
by methods A to C are shown in Fig. 2. 
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The values of 195pt-lH coupling (Table 4) are in good agreement with those 
reported by Ha et al. [19], who found values of 2Jpt_ n = 66.5 + 1.5 Hz (cis) and 
2Jpt_ H = 58 "Jr" 2 Hz (trans), respectively. 
In earlier studies on this series of complexes, method B has been used exclusively 
to prepare the substances [1-3]. Our results indicate that a mixture of the cis and the 
trans isomers for compounds 7 and 8 is obtained when method B is applied. 
Elemental analysis, the analytical method used in Refs. [1-3] to demonstrate the 
purity of the products, is clearly not suitable to distinguish between the two isomers. 
Braddock et al. [2] referred to IR absorptions in the region of the Pt-C1 
stretching vibrations to discriminate between the two isomers. Figure 3 shows the 
IR spectra of 7 and 9. 
The cis compound (lower trace) exhibits a broad absorption with a maximum 
at 321 cm- 1 and a half width of about 30 cm- 1. The trans isomer (upper trace) gives 
rise to a sharp absorption at 326cm -1 with a half width of 15cm -1. From a 
comparison of the two spectra, we see that IR spectroscopy is not capable of tracing 
small amounts of the trans isomer present as an impurity in the cis isomer. 
Biological Tests 
Effect of the Pt-Complexes on Proliferating Cultures 
The dichlorobis(cycloalkylamine)platinum(II) complexes 3 to 10 were tested on 
the human MDA-MB-231 breast cancer cell line. Cisplatin (1) and carboplatin (2) 
[cis-diamminecyclobutane-l,l-dicarboxylatoplatin(II)] were used as standards (see 
Fig. 4). 
In order to provide the most information, the data are presented as corrected 
T/C values (in ~) plotted versus time of drug exposure. An average growth curve 
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Fig. 4. A Effect of cisplatin on proliferating MDA-MB-231 cells: Plot of corrected T/C values versus 
time of drug exposure, where T is absorbance of treated cells and C is that of the untreated (A, 1 gM; ©, 
5 jaM; [2, 10 jaM); • absorbance of the dimethylformamide controls. The values represent an average 
growth curve (dashed line) of all untreated cells. The error-bars represent he standard deviation of 
the mean. B Effect of carboplatin on proliferating MDA-MB-231 cells: Corrected T/C values as a 
function of incubation time (A  1 jaM; ©, 5 gM; [3, 10 gM) 
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Fig. 5. Effect of compounds 3 (A), 4 (B), 5 (C), and 6 (D) on proliferating MDA-MB-231 cells: Corrected 
T/C values are presented as a function of incubation time (A, 1 p.M; ©, 5 gM; D, 10 gM) 
(absorbance plotted versus time) of the cells which were only exposed to the pure 
solvent is included in Fig. 4A. No change or an increase in (T/C)corr (~o) values with 
time of drug exposure represent primary drug resistance. A gradual decrease in 
(T/C)corr (~) values with time indicates an inhibition of cell growth (i.e., a slowing 
down or a stopping of cell proliferation). When the control has reached the plateau 
phase parallelism of the (T/C),orr (~) curve with the t-axes indicates cytostatic drug 
effects. Increasing (T/C)~o~ r (~o) values either reflect recovery of the cells from 
drug-induced amage, which may result in full reproductive integrity of the cultures 
(i.e., development of Secondary resistance) or inactivation of the drug. (T/C)~o~ (~) 
values < 0 indicate cytocidal drug action. 
Figure 4A shows the effect of cisplatin (1) on the MDA-MB-231 breast cancer 
cell line. At the lowest concentration (1 gM) the maximum inhibition of the cells was 
50~o after 99 h. After 147 h (the last time point of cell growth determination) the 
cells recovered up to ~ 70~ of the net cell proliferation of the control at the end of 
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Fig. 6. Effect of compounds 7 (A), 8 (B), 9 (C), and 10 (D) on proliferating MDA-MB-231 cells: 
Corrected T/C values are presented asa function of incubation time (A 1 laM; (3, 5 gM; [~, 10 gM) 
this experiment. With increasing cisplatin concentration, a clear dose-dependent 
inhibition was observed. 
Carboplatin (2) shows an inhibition of ~49~ after 123h only at the highest 
concentration (see Fig. 4B). These experimental result confirms the fact that cisplatin 
is 10 times more effective than carboplatin (at an equimolar dose). 
In the cis-series, compounds 3 to 6 show a very similar behaviour in the tests 
against he MDA-MB-231 cell line (see Fig. 5). Their inhibitory effects lie between 
those of cisplatin and of carboplatin, respectively. 
In each case, no inhibition was observed for the lowest concentration (1gM) 
used in the experiment. Higher concentrations induce dose dependent (except 
compound 5) inhibition of cell proliferation resulting in a cytostatic drug effect at 
the 10 gM concentration. At the highest concentration (10 gM) the maximum effect 
does not increase significantly with the number of carbon atoms in the cycloalkyl- 
amine ligand. Compound 3 shows a maximum inhibition of ,,~ 78~, 4 of ~ 84~, 5 
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Fig. 7. Effect ofinhibitorsATP synthesis and platinum complexes onnon-proliferatingMDA-MB-231 
cells. In contrast to routine chemosensitivity testing, the drugs were added to confluent cultures and 
the kinetics of cell death was monitored. A (~) 100 ~tM 2,4-dinitrophenol; (c~) 0.5 ~tM rotenone. B All 
platinum complexes were assayed ata concentration f 10 ~tmols/1. (*)cisplatin; compounds (e) 5; 
(11) 6; ( . )  7; (A) 8; (~) 9; (•) 10 
of ~ 86}/0, and 6 of ~ 92}/0. Similarly, at the 5 gM concentration the antitumor effect 
of 3-6 does not depend Clearly on the size of the cycloalkyl ring. All compounds 
show comparable activities. Treated cells recover after 99 h (4, 5) or even earlier (3, 
6), which indicates either inactivation of the drug or development ofsecondary drug 
resistance. 
The enlargement of the ring size of the cycloalkylamine ligands to 7 or 8 carbon 
atoms leads to very active cis-dichlorobis(cycloalkylamine)platinum(II) complexes 
(7 and 8), which even produced cytocidal effects at concentrations a low as 5 ~tM 
(8) and 10 gM (7) (Fig. 6, A and B). 
The comparative t sting of the corresponding trans isomers (9 and 10) yielded 
unexpected results. Isomer 9 was similarly active as 7, and the activity of trans isomer 
10 was virtually the same as the one of 8. At 1 gM and 10 gM, respectively, the 
inhibition curves of the isomeric dichlorobis(cycloheptylamine)platinum(II) com- 
plexes (7 and 9) are comparable. A concentration of 5 gM reveals an even higher 
activity of the trans-compound 9, in comparison with the cis-compound 7. 
Compound 9gives rise to a minimum (T/C)corr-value of ~ 30~o [7: (T/C)corr ~ 50~]. 
However, a recovery of the cells is observed after 59 h of drug cell contact with 7, 
and after 99 h with 9. Regarding the isomeric dichlorobis(cyclooctylamine)plati- 
num(II)-complexes, no difference is detectable between cis and trans compounds at 
a concentration f 5 ~M. In contrast to cisplatin, which produced cytocidal effects at 
a concentration of 10 I.tM, both isomers (8 and 10) showed extremely steep dose 
response relationship being cytocidal already in the 5 ~M concentration (Fig. 6B 
and D). 
Effect of the Cycloalkylamine Ligands on Proliferating Cultures 
To exclude the possibility that the higher cycloalkylamines alone were responsible 
for the above described antiproliferative activities, the ligands (cyclopentyl- to 
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cyclooctylamine) were tested in an analogous assay. Proliferating MDA-MB-231 
cells were incubated with ligand (10 and 20 gmols/1, corresponding to the 5 and 
10 gM concentration f the Pt-complexes) for 217 h. DMF was used as control and 
cisplatin as standard anticancer drug. Whereas cisplatin inhibited cell proliferation 
at the expected extent, none of the ligands did influence the growth curve 
significantly (data not shown). In other words, the members of the homologous 
cycloalkylamine s ries (pentyl to octyl) proved to lack antitumor activity at the 
concentrations tested. 
Effect of the Pt-Complexes of Stationary Cultures 
To determine "basal" toxicity on resting cells (usually not the target of anticancer 
drugs) plateau-phase cultures of MDA-MB-231 were treated with 10 laM cisplatin 
and those dichlorobis(cycloalkylamine)platinum(II) complexes (5-10), which were 
active against proliferating breast cancer cells. "Cell-death-kinetics" were registered 
for 163 h using the crystal violet procedure. Because of their cell cycle independent 
toxicity 100 laM 2,4-dinitrophenol DNP (an uncoupling agent) and 0.5 gM rotenone 
(a powerful inhibitor of electron transport) were chosen for comparison. As shown 
in Fig. 7A both inhibitors of mitochondrial function finally lead to cell death of the 
whole population. Microscopic observation revealed that values around 95% reflect 
disintegration of all cells in the culture. The 5%-remainder originates from 
dye-retaining cell debris. In comparison with rotenone cell kill by DNP was faster. 
The results for the platinum complexes are summarized in Fig. 7B. Whereas only 
marginal toxicity was observed for cisplatin and the compounds 5 and 6, the 
cis-isomers 7and 8 caused rapid cell death. Compound 8was obviously most toxic, 
since all cells were already disintegrated after 50 h of drug exposure. At the same 
time cis-dichlorobis(cycloheptylamine)platinum(II) caused about 85% cell kill, but 
during the course of the experiment the culture partly recovered. This recovery of 
remaining cell populations can be explained by depletion and inactivation of the 
platinum complexes by reaction with cell surface constituents and biomolecules 
released in large amounts by dead cells. 
In contrast o the inhibition of cell proliferation, where the corresponding 
cis- and trans-isomers (7/9; 8/10) were almost equiactive (cf. Fig. 6A-D), the toxicity 
of the complexes with trans-geometry (9and 10) against non-proliferating cells was 
much lower (cf. Fig. 7B). 
Discussion 
The homologous cis-dichlorobis(cycloalkylamine)platinum(II) complexes (3-8) and 
the trans-isomers of 7 and 8 (i.e. compounds 9 and 10; concerning their structures 
compare Table 1) were synthesized, and the relative positions of their amine ligands 
(cis or trans) were confirmed by 1H-NMR spectroscopy. To investigate he influence 
of the ring size as well as of the coordination geometry (cis or trans) of the two 
cycloalkylamine ligands on the antitumor activity, compounds 3-10 were tested on 
the human MDA-MB-231 breast cancer cell line in vitro. Cisplatin and carboplatin 
were used as standards. As expected, carboplatin exhibited a markedly lower 
antitumor activity than cisplatin, which produced even cytocidal effects at a 
concentration of 10~tM [(T/C)cor r =-11.6] .  These considerable differences in 
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activity between the two compounds are caused by the much slower formation of 
the active diamminediaquaplatinum(II) species in the case of carboplatin. The 
exchange of the leaving groups by H20 molecules is strongly delayed for the 
cyclobutane-l,l-dicarboxylato moiety (carboplatin) compared to chloride (cis- 
platin). The antitumor effect of the cis isomers, 3-8, depends on the size of the 
cycloalkyl ring. This influence ismost obvious from the sudden rise in activity from 
the cyclohexylamine d rivative 6 to the cycloheptyl- and cyclooctylamine d rivatives 
(7 and 8). The complexes 7 and 8 are causing even cytocidal effects when used in 
concentrations a low as 5 gM (8) or 10 gM (7 and 8). Cis-dichlorobis(cyclooctyl- 
amine)platinum(II) (8 proved to be even more active than cisplatin. Within the 
group of homologues 3-6, the differences with regard to the inhibitory effect are less 
pronounced. 
In contrast to our results, Connors and coworkers [1-3] have identified 
dichlorobis(cyclopentylamine)platinum(II) (5) as the most interesting represent- 
ative of the cis-series (compounds 3-8). Compound 5 showed activity on a spectrum 
of rodent ransplantation tumors which are also influenced by cisplatin. However, 
the toxicity of 5 is much lower and its therapeutic ndex considerably higher than 
the corresponding values of cisplatin. These properties distinguished the complex 5
as a candidate for a clinical evaluation. 
In the study of Braddock et al. [2] compound 8, the most active representative 
of our in vitro test-series, was only effective in vivo when administered in extremely 
high dose (ADJ/PC6; ID9o = 230 mg/kg). Presumably, the weak in vivo effect of 8 
is caused by its special pharmacokinetical behaviour resulting from a very low water 
solubility and a high lipophilicity. 
In the following paragraphs we would like to discuss the possibility that the 
unequal antitumor activities of 3-8 could also be due to differences inthe hydrolysis 
kinetics. Dichloroplatinum(II) complexes are non-reactive "prodrugs', which exert 
+ their antitumor effects after hydrolysis into the reactive species jPtCI(H20)]  and 
especially ~Pt(H20)2] 2+ [20]. The latter aqua-complex is preferentially bonded 
to the N7 nitrogen atoms of neighboring guanine bases in one DNA strand, resulting 
in intrastrand crosslinks. It is generally accepted that intrastrand crosslinks are 
responsible for the inhibition of DNA synthesis, and thus for the antitumor activity 
of platinum(II) complexes. 
The hydrolysis kinetics of platinum(II) complexes i dependent on the strength 
of the bond (Pt-X) between platinum and the leaving roup X, in our case chloride. 
By structural variation of the latter, the rate of hydrolysis and thus the extent of 
tumor inhibition can be influenced. However, it cannot be excluded that the amine 
ligands also exert an influence on the Pt-X bond. Therefore we have used vibrational 
and NMR spectroscopies to study whether the strength of the Pt-C1 bond changes 
with increasing ring size in dichlorobis(cycloalkylamine)platinum(II) complexes. 
The influence of the cycloalkyl moiety on the electron density of the co- 
ordinated nitrogen atom may be deduced from the 1H-NMR spectra [5]. 
Cyclopropylamine requires eparate consideration [5], to account for ring current 
effects due to the unusual 60 ° bond angles in the three-membered ing. For the higher 
homologues, a growing number of carbon atoms in the cycloalkylamine r sidue 
results in a shift of the 1H-NMR resonance ofthe NH 2 groups to lower ppm values, 
owing to an increasing shielding of the NH protons. This shielding is confirmed by 
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SCAMP calculations for the pure amine ligands, which show negative charges on 
the N atom (i.e., -0.325 eo for cyclopropylamine, -0.332 e 0 for cyclobutylamine 
and cyclopentylamine, and -0.335 e o for cyclohexylamine, cycloheptylamine, and 
cyclooctylamine, respectively) [-5]. This effect should influence the electronic 
structure of the central platinum atom. However, extensive studies of the UV 
absorption and emission spectra of the complexes do not support his assumption 
[-6]. The variation of the neutral ligands produces only a small effect on the electronic 
spectra of the Pt(II)-complexes. In accordance with this result IR and Raman 
spectroscopy yield comparable values for the frequency of the Pt-C1 stretching 
vibration in the entire series [5]. All complexes exhibit an intense PtC12 symmetric 
stretching band, with a maximum near 320 cm- 1 and a half width of ~ 25 cm- 1. 
This means that the size of the cycloalkylamine ring does not entail significant 
differences in the Pt-C1 binding strength. This result is in accordance with a kinetic 
study of Braddock et al. [2]. The authors found that, with the exception of 
cis-dichlorobis(cyclopropylamine)platinum(II), all homologues show comparable 
first-order ate constants for the solvolysis in DMSO (3: k, = 17.4 x 104 S- 1; 4-8: 
k~ =9.2-6.6 x 104s-X; 60°C). In this reaction an irreversible xchange of one 
chloride ligand by DMSO is taking place. The complex with the least basic amine 
(3) proved to be significantly more labile than the others. 
In view of these results, although we found no influence of the pure 
cycloalkylamine ligands on cell proliferation, it is obvious that the amine ligand (i.e. 
the non-leaving roup) influences the cytotoxic activity of the homologous 
cis-dichlorobis(cycloalkylamine)platinum(II) complexes in another, still incom- 
pletely characterized way. Important information on this question is provided by 
physiochemical and biochemical studies of Butour et al. [21] on adducts of DNA 
with cis-[-Pt(RNH2)2(N03)2] (where R represents H, CH 3, or cyclobutyl to 
cyclohexyl). These compounds, which are immediately transformed into the 
corresponding active ~Pt(H20)2] 2+ species under physiological conditions, 
exhibit quantitative r action with DNA in less than 1 h at 37 °C forming bifunctional 
adducts with adjacent nucleotides. In spite of their fast and comparable rate of 
quantitative reaction with DNA, these compounds how differences in their 
antitumor activities [22]. Presumably these differences are caused by a destabiliza- 
tion of the secondary structure of DNA which renders the DNA-protein interaction 
more difficult. The extent of destabilization depends on the size of the alkyl residue. 
The authors tate that a disruption of DNA conformation by steric crowding of the 
non-leaving roups is unlikely. A hindrance of the solvation of DNA by the 
hydrophobic cycloalkyl residues i considered as an important aspect of drug action. 
These perturbations may have consequences forthe antitumor activity; they might 
also be important for the inhibition of resistance development bythe tumor cell. 
In a comprehensive study, Braddock et al. [2] have shown that the trans-isomers 
of homologous cis-dichlorobis(cycloalkylamine)platinum(II) complexes (3-6) pos- 
sess no substantial antitumor activity in the test on the ADJ/PC6 tumor of the 
mouse. These additional examples extend the original observation of Rosenberg 
[23] that only the cis-isomer of diamminedichloroplatinum(II) is active. Surprisingly, 
in our own experiments the comparative t sting of the cis- and trans compounds of 
dichlorobis(cycloheptylamine)platinum(II) (7/9) and dichlorobis(cyclooctylamine)- 
platinum(II) (8/10) on proliferating MDA-MB-231 breast cancer cells yielded nearly 
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the same activity pattern for the related isomeric pairs. Comparable xamples where 
the cis and trans isomers are similarly active were detected in the class of 
dichlorobis(pyridyl)platinum(II) complexes by Farrell et al. [24]. The compounds 
produced a weaker inhibition of the L1210 and P388 leukemia of the mouse than 
cisplatin. 
Likewise, the rule that monofunctional p atinum(II) complexes, which contain 
3 amine ligands and only one leaving group such as CI-, are inactive, has been 
disproved by Hollis et al. [25]. The authors howed that such complexes inhibit the 
growth of several tumor models, inspite of their ability to react only with one 
nucleophilic enter of the DNA. [For a more extensive discussion of the structure 
activity-relationship of platinum(II) complexes, the reader is referred to reviews in 
the literature [-26-30].] 
The great differences in the antitumor activities of the stereoisomers of 
diamminedichloroplatinum(II) cisplatin is a very potent drug, transplatin is 
ineffective) are attributed to a faster epair of the transplatin-DNA lesions [31-34]. 
The repair-resistant intrastrand crosslinks are formed by cisplatin but not by its 
trans isomer, for stereochemical reasons. Transplatin reacts exclusively with 
nucleotides in opposing DNA strands and forms interstrand crosslinks, which are 
also hardly accessible to repair [35]. However, the interstrand crosslinks are found 
with a lower frequency, which is a possible reason for the inactivity of transplatin 
against umors [35]. It is believed that only the bifunctional adducts but not the 
monofunctional ones, which are primarily formed in the reaction of transplatin with 
DNA, can escape the repair by enzymes [29]. This assumption was confirmed by 
investigations ofBernges et al. [36, 37-1 on the repair of cis- and transplatin-treated 
DNA by E. coli DNA polymerase I. This enzyme contains DNA polymerase as well 
as exonuclease activity (i.e., proofreading and repair functions). In contrast to 
bifunctional Pt-adducts (i.e. crosslinks), the monofunctional adducts which are 
preferentially formed by transplatin, are sensitive to degradation by this enzyme. 
Intrastrand crosslinks, especially between adjacent guanosine molecules, are not 
efficiently recognized and repaired. Therefore they accumulate in the DNA leading 
to the antitumor effect of cisplatin [33]. 
The surprising result of this study that trans-dichlorobis(cycloalkylamine)plati- 
num(II) complexes with large 7- or 8-membered rings (compounds 9 and 10) possess 
inhibitory activities comparable to those of their cis-isomers (7 and 8), could be 
explained from the evidence summarized in the preceding paragraphs as follows. 
Most likely, mono- but not bis-adducts with DNA are formed by the trans 
configurated platinum(II) compounds 9 and 10. In these adducts, the bulky 
lipophilic non-leaving amine groups destabilize the secondary structure of DNA, 
and thereby the protein-DNA interactions. This perturbation should influence the 
recognition and the repair of platinum-DNA adducts of 9 and 10 (compare Refs. 
[21] and [25]). 
A more plausible reason for the remarkable antiproliferative (cf. Fig. 6A-D) and 
toxic (cf. Fig. 7B) potential of the higher dichlorobis(cycloalkylamine)platinum(II) 
homologues 7-10 appears to come from their high lipophilicity. Souchard et al., 
who have measured hydrophobicity parameters of the nitrato analogues of the 
complexes 4-7, found a striking discontinuity among this series [22]. If the relative 
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hydrophobicity ofthe cyclobutylamine d rivative is defined 1.0, the corresponding 
values for the complexes containing the cyclopentyl, cyclohexyl and cycloheptyl 
moieties were 3.7, 6.3, and 23.0, respectively. In contrast o the work of Braddock 
et al. [2] who did not observe a correlation between lipophilicity and antitumor 
activity, our data seem to be consistent with this steep increase in lipophilicity: both, 
antiproliferative activity and "basal" toxicity against he MDA-MB-231 human 
breast cancer cell line parallel the increase of the hydrophobicities of the compounds 
6 and 7. 
Although it has been proposed that large lipophilic ligands might facilitate drug 
transport across cell membranes [22], lipophilicity appears to be a critical factor. 
In a previous study, our group has shown that extremely lipophilic platinum 
complexes ofthe 1,2-diphenylethylenediamine-type wi h stearate l aving roups are 
trapped in the lipid bilayer of erythrocyte ghosts [38]. As a consequence such 
compounds cannot react with DNA, generally agreed with as the main target of 
platinum anticancer drugs. Braddock and coworkers [2] have already doubted that 
all members of the homologue series of dichlorobis(cycloalkylamine)platinum(II) 
complexes have the same mechanism of action. Considering the preceding 
argumentation, it is conceivable that the marked antiproliferative activity of the 
compounds 7-10 results from a combination of effects as inhibition of DNA 
synthesis and interference with cell membrane integrity, as a function of platination 
of essential membrane constituents e.g. unsaturated fatty acids, surface and integral 
proteins. This hypothesis supported by the experiments on static, non-dividing 
(i.e. there is no DNA synthesis) populations of MDA-MB-231 cells. Whereas cisplatin 
(its main mechanism ofaction is interference with DNA synthesis by the formation 
of bifunctional cross links) was only marginally toxic, the higher dichlorobis(cyclo- 
alkylamine)platinum(II) complexes caused disintegration of the cells. In contrast 
to Braddock et al. [2] who reported slightly higher toxicities for the isomers with 
trans geometry, our data clearly show that the trans-isomers are much less toxic 
(cf. Fig. 7B). The detection of these differences was achievable by using almost 
confluent cultures, since the extent of cytotoxicity is influenced by the cell density 
seeded [4], i.e. it increases with decreasing cell number. By conventional chemosen- 
sitivity assays (using low initial cell densities) gradual differences in toxicity will not 
be detected, since the resolution of these assays is limited by their high sensitivity, 
especially when drugs produce cytocidal effects. The reduced toxicity of the 
trans-isomers might be explained with the formation of monofunctional dducts 
with membrane constituents causing less damage to the cell. 
Although the value of the higher dichlorobis(cycloalkylamine)platinum(II) 
complexes as potential anticancer drugs is compromised by their high "basal" 
toxicities, they can serve as useful tools for getting more insight into the mode of 
action of cisplatin analogues in further mechanistic studies. 
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